Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs RIGL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: VNDA 0 – 6 RIGL Matrix Metrics: VNDA 2 – 8 RIGL

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin).

  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs RIGL
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.74
-1.61% 1D
Market Cap $860.3M
TTM Revenue $288M
Forward P/E 9.3x
Beta / 30D Vol 1.06β · 74% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.6 · SMA20: $47.42 · SMA50: $47.34

6-Pillar Scorecard Institutional Category Breakdown (VNDA 0 – 6 RIGL)

Columns: Metric · VNDA · RIGL
1. Valuation Multiples RIGL
Forward P/E 103.1x 9.3x
Trailing P/E 103.1x 2.8x
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 2.9x
2. Growth & Scale RIGL
Revenue Growth (YoY) +24.1% +16.5%
Earnings Growth (YoY) -95.9% -55.5%
TTM Revenue (USD) $229M $288M
Market Cap $238.9M $860.3M
3. Profitability & Quality RIGL
Gross Margin 93.6% 70.7%
Operating Margin -77.6% 26.3%
Net Profit Margin -119.9% 106.6%
Return on Equity (ROE) -82.5% 109.2%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) -$150M $19M
Cash Flow Margin -65.4% 6.7%
Net Cash / Leverage $40M Net Cash $39M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RIGL
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 163.3% (75th %ile) 61.2% (4th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RIGL
OpEx & R&D Intensity N/A 44.4% of Rev ($128M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (2) vs RIGL (8)
Institutional Metric VNDA RIGL Criterion Row Edge
Market Capitalization
Scale
$238.9M $860.3M Larger Scale RIGL
Trailing P/E Ratio
Valuation
103.1x 2.8x Lower Multiple RIGL
Forward P/E Ratio
Valuation
103.1x 9.3x Lower Multiple RIGL
Revenue Growth (YoY)
Growth
+24.1% +16.5% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% 26.3% Higher Margin RIGL
Net Profit Margin
Profitability
-119.9% 106.6% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
-82.5% 109.2% Higher ROE RIGL
52-Week Range Position
Momentum
4% ($4–$10) 68% ($25–$53) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.06β · 74% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 59.9 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$229M $288M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 70.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 2.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) $19M ($39M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RIGL +0.99 pp
VNDA: -5.83% · RIGL: -4.84%
3M Horizon RIGL +30.53 pp
VNDA: -30.24% · RIGL: +0.29%
6M Horizon RIGL +90.48 pp
VNDA: -37.58% · RIGL: +52.9%
1Y Horizon RIGL +22.25 pp
VNDA: -12.56% · RIGL: +9.69%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue RIGL Revenue VNDA Op. Margin RIGL Op. Margin Margin Leader
FY2018 $190M $40M 11.3% -163.3% VNDA
FY2019 $230M $60M 10.0% -116.5% VNDA
FY2020 $250M $110M 11.0% -26.7% VNDA
FY2021 $270M $150M 15.7% -8.4% VNDA
FY2022 $250M $120M 2.5% -46.2% VNDA
FY2023 $190M $120M -7.2% -17.5% VNDA
FY2024 $200M $180M -20.5% 13.5% RIGL
FY2025 $220M $290M -70.0% 42.6% RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RIGL CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 61.2%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs RIGL Key Questions & Quantitative Answers

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RIGL leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with RIGL at +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while RIGL shifted +625.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($128M) (0 disclosures) for RIGL.

RIGL screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus RIGL (109.2% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.